Published in PLoS One on September 09, 2014
The Effect of Renal Function Impairment on the Mortality of Cirrhotic Patients: A Nationwide Population-Based 3-Year Follow-up Study. PLoS One (2016) 0.77
Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus. World J Hepatol (2016) 0.76
Renal dysfunction in cirrhosis. Curr Opin Gastroenterol (2015) 0.75
Hepatorenal syndrome: Update on diagnosis and therapy. World J Hepatol (2017) 0.75
Renal failure in cirrhosis: Emerging concepts. World J Hepatol (2015) 0.75
Acute Kidney Injury in Patients with Cirrhosis. J Clin Transl Hepatol (2015) 0.75
Outcomes of liver transplantation in patients with hepatorenal syndrome. World J Hepatol (2016) 0.75
Current position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome. World J Gastrointest Pharmacol Ther (2015) 0.75
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (2009) 22.18
Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology (1996) 4.54
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut (2007) 4.51
Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology (1993) 3.28
Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol (2009) 2.92
Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology (2008) 2.89
A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology (2008) 2.69
Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology (2002) 2.56
Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol (2007) 2.12
Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. J Gastroenterol Hepatol (2009) 1.65
An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol (2008) 1.27
Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology (2010) 1.21
Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol (2012) 1.00
Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev (2012) 0.99
Causes of renal failure in patients with decompensated cirrhosis and its impact in hospital mortality. Ann Hepatol (2011) 0.96
Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis. Int Urol Nephrol (2010) 0.96
Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: a meta-analysis. Indian J Pharmacol (2013) 0.94
Management of hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol (2011) 0.92
Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice. J Hepatol (2012) 0.91
Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol (2011) 0.90
Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int (2013) 0.87
Effect of terlipressin on blood volume distribution in patients with cirrhosis. Scand J Gastroenterol (2004) 0.80